Maxim Group reiterated their buy rating on shares of Beigene (NASDAQ:BGNE) in a research note released on Wednesday.

“BeiGene announced the commercial availability of Celgene’s VIDAZA. Recall that VIDAZA is an injectable nucleoside metabolic inhibitor for patients with Intermediate-2/high-risk myelodysplastic syndrome (MDS), AML with 20-30% bone marrow blasts and chronic myelomonocyte leukemia (CMML). The asset is the third product in BeiGene’s China commercial portfolio along with Abraxane and Revlimid and positions BeiGene to be a leader in the oncology space in China.”,” Maxim Group’s analyst commented.

A number of other analysts also recently commented on BGNE. Zacks Investment Research downgraded Beigene from a hold rating to a sell rating in a report on Monday, November 13th. Robert W. Baird restated a neutral rating and set a $83.00 price objective (up from $58.00) on shares of Beigene in a report on Tuesday, November 14th. Cowen restated a buy rating on shares of Beigene in a report on Tuesday, November 14th. ValuEngine downgraded Beigene from a hold rating to a sell rating in a report on Wednesday, January 3rd. Finally, BidaskClub upgraded Beigene from a hold rating to a buy rating in a report on Friday, January 5th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company has an average rating of Buy and a consensus price target of $96.67.

Beigene (NASDAQ:BGNE) opened at $125.48 on Wednesday. The company has a quick ratio of 9.27, a current ratio of 9.33 and a debt-to-equity ratio of 0.20. The firm has a market capitalization of $6,490.37, a price-to-earnings ratio of -96.52 and a beta of 0.61. Beigene has a twelve month low of $34.36 and a twelve month high of $142.00.

Beigene (NASDAQ:BGNE) last released its quarterly earnings data on Monday, November 13th. The company reported $2.54 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $2.31. The firm had revenue of $220.21 million for the quarter, compared to analyst estimates of $1.55 million. During the same quarter in the previous year, the company earned ($1.08) earnings per share. equities research analysts anticipate that Beigene will post -2.04 earnings per share for the current fiscal year.

In related news, Director Bros. Advisors Lp Baker purchased 1,980,198 shares of the stock in a transaction that occurred on Thursday, January 18th. The stock was purchased at an average cost of $101.00 per share, for a total transaction of $199,999,998.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO John Oyler sold 20,137 shares of the stock in a transaction on Tuesday, December 26th. The shares were sold at an average price of $96.46, for a total value of $1,942,415.02. Following the completion of the sale, the chief executive officer now owns 110,179 shares of the company’s stock, valued at $10,627,866.34. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 483,482 shares of company stock valued at $42,139,474. Insiders own 19.90% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Orbimed Advisors LLC increased its holdings in Beigene by 2.0% in the 3rd quarter. Orbimed Advisors LLC now owns 1,313,788 shares of the company’s stock valued at $135,925,000 after purchasing an additional 26,200 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in Beigene in the 3rd quarter valued at $62,076,000. BlackRock Inc. increased its holdings in Beigene by 3.8% in the 4th quarter. BlackRock Inc. now owns 357,577 shares of the company’s stock valued at $34,942,000 after purchasing an additional 13,232 shares in the last quarter. Janus Henderson Group PLC acquired a new stake in Beigene in the 3rd quarter valued at $33,744,000. Finally, Artal Group S.A. increased its holdings in Beigene by 33.3% in the 4th quarter. Artal Group S.A. now owns 300,000 shares of the company’s stock valued at $29,316,000 after purchasing an additional 75,000 shares in the last quarter. Hedge funds and other institutional investors own 47.52% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Beigene (BGNE) Given Buy Rating at Maxim Group” was first published by Daily Political and is the property of of Daily Political. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.dailypolitical.com/2018/02/10/beigene-bgne-given-buy-rating-at-maxim-group.html.

About Beigene

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

Analyst Recommendations for Beigene (NASDAQ:BGNE)

Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.